Previous 10 | Next 10 |
BOSTON, May 28, 2020 (GLOBE NEWSWIRE) -- resTORbio (Nasdaq: TORC) today announced the initiation of a randomized, double-blind, placebo-controlled trial of RTB101, an investigational orally-administered potent small molecule inhibitor of target of rapamycin complex 1 (TORC1), as compared to...
NEW YORK, NY / ACCESSWIRE / May 11, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the p...
NEW YORK, NY / ACCESSWIRE / May 11, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: resTORbio, Inc. (NASDAQ: TORC ) relating to the ...
resTORbio (NASDAQ: TORC ): Q1 GAAP EPS of -$0.19 beats by $0.15 . More news on: resTORbio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
BOSTON, May 07, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today provided a corporate update and reported financial results f...
NEW YORK, NY / ACCESSWIRE / May 5, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the pr...
NEW YORK , May 5, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City , is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ul...
NEW YORK, NY / ACCESSWIRE / May 4, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the pr...
resTORbio ( TORC ) shares have suffered since the company announced the failure of a Phase 3 trial for their lead asset, RTB101, last November. Since then, the company has traded at a market cap well below the level of its net cash. This week resTORbio announced a reverse merger with Adicet Bi...
NEW YORK, NY / ACCESSWIRE / April 30, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the...
News, Short Squeeze, Breakout and More Instantly...
- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology - -Trading to Commence on September 16, 2020 on The Nasdaq Global Market Under Ticker Symbol “ACET”- MENLO PARK, Calif. and BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -...
MENLO PARK, Calif. , Aug. 5, 2020 /PRNewswire/ -- Adicet Bio, Inc., a privately-held biopharmaceutical company, today announced that it has received a $10 million milestone payment from Regeneron associated with ADI-002 meeting key preclinical development goals, in accordance with the t...
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today provided a corporate update and reported financial results ...